Semaglutide and eating disorder risk

Semaglutide is the medication behind two of the most talked-about drug brands of the decade: Ozempic, approved for type 2 diabetes, and Wegovy, approved for chronic weight management. It is a GLP-1 receptor agonist that works largely by suppressing appetite and slowing how quickly the stomach empties.¹ This page focuses on what is actually known about semaglutide and eating disorder risk: what the evidence shows, what it does not, who is most vulnerable, and what safe use looks like. For the broader brand overview, see Ozempic and eating disorders.

How semaglutide works, and why that matters here

Semaglutide mimics GLP-1, a gut hormone that signals fullness and slows digestion.¹ The practical effect is that people feel full sooner, stay full longer, and eat less without much effort. In its main weight-management trial, the highest dose produced average weight loss of roughly 15 percent of body weight over about 68 weeks.² That effectiveness is the reason the drug is prescribed, and the basis on which the FDA approved it for chronic weight management.³

It is also the source of the eating disorder concern. The two effects that make semaglutide work, powerful appetite suppression and meaningful weight loss, are well-established triggers for disordered eating in people who are vulnerable.⁴ A drug that makes eating less feel effortless can quietly reinforce restriction in someone prone to it, and rapid weight loss can set off or deepen an eating disorder regardless of how the loss is achieved.

What the evidence does and does not say

What the trials tested matters here. The large clinical trials that established semaglutide's safety and effectiveness generally excluded people with eating disorders.² That means the drug's effects in people with eating disorder histories are not well studied, and the caution here is based on the drug's known mechanism and on clinical experience, not on direct trial evidence in that population.

So the accurate statement is not "studies prove semaglutide causes eating disorders." It is narrower and more useful: the drug's core effects are recognized risk factors for disordered eating, the people most at risk were largely left out of the research, and clinicians who treat eating disorders therefore approach it with care.⁴ Absence of trial evidence in a population is not evidence of safety in that population.

Who is most vulnerable

The risk is not evenly spread. It concentrates in identifiable groups, and recognizing yourself or a loved one here is a reason for a careful conversation with the prescriber, not necessarily a reason to avoid treatment.

Using semaglutide safely

For people with a genuine medical indication and no eating disorder vulnerability, semaglutide is a prescribed treatment used under supervision, and most use it without trouble. Safety is individual, and a few steps protect it. The single most important is disclosure: tell the prescriber about any eating disorder history before starting, even if it was years ago, because that history can change whether the drug is appropriate at all. Beyond that, eat enough to meet your body's needs even when appetite is low, keep regular follow-up so weight and eating patterns are watched by someone other than you, and treat any new fear of food or weight regain as something to raise rather than manage alone.

If use has tipped into something disordered

Watch for restriction beyond what was prescribed, using the appetite suppression to eat far less than your body needs, fear of regaining weight, distress at the idea of stopping, preoccupation with the scale, or any return of eating disorder behaviors. Our guide on the signs that weight-loss medication use has become disordered covers these in detail. If you recognize them, talk to a professional, and do not stop a prescribed medication abruptly without medical advice.

Related reading

For questions specific to weight-loss use, see Wegovy and disordered eating; for the diabetes-brand overview, see Ozempic and eating disorders; for the newer dual-action drug, see Mounjaro, tirzepatide, and eating disorders.